These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 37408759)

  • 21. Tislelizumab Plus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (RATIONALE 304): A Randomized Phase 3 Trial.
    Lu S; Wang J; Yu Y; Yu X; Hu Y; Ai X; Ma Z; Li X; Zhuang W; Liu Y; Li W; Cui J; Wang D; Liao W; Zhou J; Wang Z; Sun Y; Qiu X; Gao J; Bao Y; Liang L; Wang M
    J Thorac Oncol; 2021 Sep; 16(9):1512-1522. PubMed ID: 34033975
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and Safety of First-Line Immunotherapy Combinations for Advanced NSCLC: A Systematic Review and Network Meta-Analysis.
    Liu L; Bai H; Wang C; Seery S; Wang Z; Duan J; Li S; Xue P; Wang G; Sun Y; Du X; Zhang X; Ma Z; Wang J
    J Thorac Oncol; 2021 Jul; 16(7):1099-1117. PubMed ID: 33839365
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The benefits and risks of CTLA4 inhibitor plus PD1/PDL1 inhibitor in stage IIIB/IV non-small cell lung cancer: A systematic analysis and meta-analysis based on randomized controlled trials.
    Liu Q; Fang Z; Liu M; Xu R; Yi F; Wei Y; Zeng L; Zhang W
    J Clin Pharm Ther; 2021 Dec; 46(6):1519-1530. PubMed ID: 34101874
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1?
    Zhang Y; Zhou H; Zhang L
    J Immunother Cancer; 2018 Dec; 6(1):135. PubMed ID: 30509312
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Network Meta-Analysis of Cancer Immunotherapies
    Herbst R; Jassem J; Abogunrin S; James D; McCool R; Belleli R; Giaccone G; De Marinis F
    Front Oncol; 2021; 11():676732. PubMed ID: 34307144
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of the efficacy and safety in the treatment strategies between chemotherapy combined with antiangiogenic and with immune checkpoint inhibitors in advanced non-small cell lung cancer patients with negative PD-L1 expression: A network meta-analysis.
    Li J; Chen Y; Hu F; Qiang H; Chang Q; Qian J; Shen Y; Cai Y; Chu T
    Front Oncol; 2022; 12():1001503. PubMed ID: 36523992
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of first-line PD-1/PD-L1 inhibitor combinations for extensive-stage small-cell lung cancer: a Bayesian network meta-analysis.
    Li H; Han H; Li C; Wu R; Wang Z; Wang Y; Zhan P; Lv T; Zhang F; Song Y; Liu H
    Ther Adv Med Oncol; 2023; 15():17588359231189430. PubMed ID: 37885460
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of atezolizumab, durvalumab, pembrolizumab, and nivolumab as first-line treatment in patients with extensive-stage small cell lung cancer: A systematic review and network meta-analysis.
    Chen J; Wang J; Xu H
    Medicine (Baltimore); 2021 Apr; 100(15):e25180. PubMed ID: 33847617
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identifying optimal PD-1/PD-L1 inhibitors in first-line treatment of patients with advanced squamous non-small cell lung cancer in China: Updated systematic review and network meta-analysis.
    Zhao M; Shao T; Ren Y; Zhou C; Tang W
    Front Pharmacol; 2022; 13():910656. PubMed ID: 36249794
    [No Abstract]   [Full Text] [Related]  

  • 30. Network meta-analysis of immune-oncology monotherapy as first-line treatment for advanced non-small-cell lung cancer in patients with PD-L1 expression ⩾50.
    Freemantle N; Xu Y; Wilson FR; Guyot P; Chen CI; Keeping S; Konidaris G; Chan K; Kuznik A; Atsou K; Glowienka E; Pouliot JF; Gullo G; Rietschel P
    Ther Adv Med Oncol; 2022; 14():17588359221105024. PubMed ID: 35747163
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term comparative efficacy and safety of nivolumab plus ipilimumab relative to other first-line therapies for advanced non-small-cell lung cancer: A systematic literature review and network meta-analysis.
    O'Byrne K; Popoff E; Badin F; Lee A; Yuan Y; Lozano-Ortega G; Eccles LJ; Varol N; Waser N; Penrod JR; Goring S
    Lung Cancer; 2023 Mar; 177():11-20. PubMed ID: 36669321
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An Indirect Comparison Between Nivolumab + Ipilimumab + Two Cycles of Chemotherapy vs. Pembrolizumab + Chemotherapy as First-Line Treatment for Metastatic Non-Small Cell Lung Cancer.
    Jiang P; Mao Z; Wang Q; Jia X; Geng L; Xu H; Jiang L; Yang C; Jiao M; Guo H
    Front Oncol; 2021; 11():698199. PubMed ID: 34589422
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative efficacy and safety of PD-1/PD-L1 Inhibitors versus platinum-based chemotherapy for the first-line treatment of advanced non-small cell lung cancer: a meta analysis of randomized controlled trials.
    Li ZQ; Yan HC; Gu JJ; Yang YL; Zhang MK; Fang XJ
    Pharmacol Res; 2020 Oct; 160():105194. PubMed ID: 32937178
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PD-1 inhibition plus platinum-based chemotherapy (PBC) or PBC alone in the first-line treatment of locally advanced or metastatic pulmonary lymphoepithelioma-like carcinoma.
    Zhang X; Zhou Y; Chen H; Chen C; Lin Z; He LN; Du W; Chen T; Hong S; Fu S
    Front Immunol; 2022; 13():1015444. PubMed ID: 36248788
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Optimal first-line treatment for platinum-eligible metastatic urothelial carcinoma: Comparison of chemo-immunotherapy, immunotherapy, and chemotherapy- A systematic review and meta-analysis.
    Li H; Ni M; Xue C; Li L; Huang R; Yang W; Hu A; An X; Shi Y
    Clin Immunol; 2022 Mar; 236():108927. PubMed ID: 35031491
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immune-related adverse events of a PD-L1 inhibitor plus chemotherapy versus a PD-L1 inhibitor alone in first-line treatment for advanced non-small cell lung cancer: A meta-analysis of randomized control trials.
    Wang M; Liang H; Wang W; Zhao S; Cai X; Zhao Y; Li C; Cheng B; Xiong S; Li J; He J; Liang W
    Cancer; 2021 Mar; 127(5):777-786. PubMed ID: 33119182
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies.
    Nosaki K; Saka H; Hosomi Y; Baas P; de Castro G; Reck M; Wu YL; Brahmer JR; Felip E; Sawada T; Noguchi K; Han SR; Piperdi B; Kush DA; Lopes G
    Lung Cancer; 2019 Sep; 135():188-195. PubMed ID: 31446994
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The safety and efficacy of tislelizumab, alone or in combination with chemotherapy, for the treatment of non-small cell lung cancer: a systematic review of clinical trials.
    Daei Sorkhabi A; ZareDini M; Fazlollahi A; Sarkesh A; Naseri A; Mousavi SE; Nejadghaderi SA; Sullman MJM; Kolahi AA; Safiri S
    BMC Pulm Med; 2023 Dec; 23(1):495. PubMed ID: 38066549
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of first-line immunotherapy plus chemotherapy in treating patients with extensive-stage small cell lung cancer: a Bayesian network meta-analysis.
    Zhang T; Li W; Diwu D; Chen L; Chen X; Wang H
    Front Immunol; 2023; 14():1197044. PubMed ID: 37435087
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A systematic review and network meta-analysis of first-line immune checkpoint inhibitor combination therapies in patients with advanced non-squamous non-small cell lung cancer.
    Shao T; Zhao M; Liang L; Tang W
    Front Immunol; 2022; 13():948597. PubMed ID: 36389713
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.